FULC NASDAQ
Fulcrum Therapeutics, Inc.
1W: -7.3%
1M: -15.0%
3M: -40.1%
YTD: -39.6%
1Y: +1.2%
3Y: +73.4%
5Y: -33.0%
$6.57
-0.02 (-0.30%)
Weekly Expected Move ±7.1%
$6
$6
$7
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (42)
After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)
Fulcrum (FULC) Q1 2026 Earnings Transcript
Earnings Scheduled For April 27, 2026
Fulcrum Therapeutics GAAP EPS of -$0.25 beats by $0.05
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Increases By 41.1%
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Aberdeen Group plc Has $14.18 Million Stock Holdings in Fulcrum Therapeutics, Inc. $FULC
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Brokerages
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Analysts
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript
Fulcrum Therapeutics GAAP EPS of -$0.31 in-line
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC
Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Contrasting Fulcrum Therapeutics (NASDAQ:FULC) & VistaGen Therapeutics (NASDAQ:VTGN)
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock
Fulcrum Therapeutics (NASDAQ:FULC) Sees Strong Trading Volume on Analyst Upgrade
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 7.8% After Analyst Upgrade
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results
Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025